This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers, clinicians and innovators. The series will help attendees anticipate, access, and apply new approaches and technologies for patient care.
The Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
To register, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ
2024-2025 Leading Strand from 12:00pm – 1:00pm ET, scheduled dates are:
Friday September 27, 2024
Friday October 25, 2024
Psychiatric Phenotyping and Precision Prescribing for Rare Genetic Conditions
This presentation will begin by describing the high rate and heterogeneous presentations of neuropsychiatric disorders in rare genetic conditions. Current research efforts to improve psychiatric phenotyping across the lifespan in rare genetic conditions will be discussed. The contemporary use of language and diagnostic terms with respect to neurodevelopmental and neuropsychiatric disorders will be summarized. The limited evidence to inform prescribing practices for behavioural and psychiatric disorders in rare genetic conditions will then be reviewed.
Learning objectives:
- Describe the high rate and heterogeneous presentations of neuropsychiatric disorders in rare and ultra rare genetic conditions.
- Understand current research efforts to improve psychiatric phenotyping across the lifespan in rare genetic conditions.
- Appreciate the limited evidence to inform prescribing practices for behavioural and psychiatric disorders in rare genetic conditions.
Speaker: Dr, Danielle Baribeau
Dr. Danielle Baribeau is a child and adolescent psychiatrist and clinician-scientist at Holland Bloorview Kids Rehabilitation Hospital in Toronto. Her clinical focus is in autism, rare genetic neurodevelopmental disorders, and psychopharmacology. She is also the lead of the Ontario Provincial Genetics Program Expert Group for genetic testing in neurodevelopmental disorders. Her CIHR funded research program is focused on clinically translating genetic advances into improved mental health care in autism and neurodevelopmental disorders. Her current studies use health administrative data to examine health system outcomes in autism and rare genetic diseases from across Ontario. She is the site- or principal investigator for several clinical trials of medications for behavioural and mental health outcomes in autism.
Friday November 22, 2024
Friday December 13, 2024
Friday, January 31, 2025
Friday February 28, 2025
Friday, March 28, 2025
Friday, April 25, 2025
Friday, May 30, 2025
Friday June 27, 2025
Friday, May 16, 2025
Friday, June 20, 2025
